Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $166.4 million.

  • Akebia Therapeutics' Cash & Equivalents rose 38926.78% to $166.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.4 million, marking a year-over-year increase of 38926.78%. This contributed to the annual value of $51.9 million for FY2024, which is 2083.87% up from last year.
  • Per Akebia Therapeutics' latest filing, its Cash & Equivalents stood at $166.4 million for Q3 2025, which was up 38926.78% from $137.3 million recorded in Q2 2025.
  • Akebia Therapeutics' Cash & Equivalents' 5-year high stood at $252.8 million during Q1 2021, with a 5-year trough of $34.0 million in Q3 2024.
  • Over the past 5 years, Akebia Therapeutics' median Cash & Equivalents value was $113.4 million (recorded in 2025), while the average stood at $115.5 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Cash & Equivalents plummeted by 6786.67% in 2023, and later skyrocketed by 38926.78% in 2025.
  • Akebia Therapeutics' Cash & Equivalents (Quarter) stood at $149.8 million in 2021, then tumbled by 39.61% to $90.5 million in 2022, then crashed by 52.55% to $42.9 million in 2023, then rose by 20.84% to $51.9 million in 2024, then skyrocketed by 220.89% to $166.4 million in 2025.
  • Its last three reported values are $166.4 million in Q3 2025, $137.3 million for Q2 2025, and $113.4 million during Q1 2025.